Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Industry News

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

July 21, 2021

News Industry News

Conformal Medical's CLAAS® Stroke Prevention Technology Announces Promising Clinical Results at 2020 TCT Conference

October 15, 2020

News Industry News

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

May 22, 2019

News Industry News

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

October 03, 2016

News Industry News

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

November 19, 2015

News Industry News

Good Samaritan Hospital Offers an Alternative to Long-Term Warfarin Medication for Atrial Fibrillation with Newly Approved Watchman™ LAAC Implant

May 18, 2015

News Industry News

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

March 24, 2015

News Industry News

FDA Advisory Committee Panel Votes In Favor Of The WATCHMAN™ Left Atrial Appendage Closure Device

October 08, 2014

News Industry News

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

September 10, 2014

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

Advertisement

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

Conformal Medical's CLAAS® Stroke Prevention Technology Announces Promising Clinical Results at 2020 TCT Conference

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Good Samaritan Hospital Offers an Alternative to Long-Term Warfarin Medication for Atrial Fibrillation with Newly Approved Watchman™ LAAC Implant

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

FDA Advisory Committee Panel Votes In Favor Of The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content